Results 141 to 150 of about 1,336,088 (341)

Assessment of Oncology Advanced Practice Professional Willingness to Participate in Medical Aid in Dying [PDF]

, 2022
Jonathan Singer, Courtney Daum, Megan Johnson Shen, Gabrielle Zecha, Louise Kaplan, Kathy Plakovic, Meagan Blazey, Molly Arnold, Barbara Silko, Kelsey K. Baker, Elizabeth T. Loggers   +10 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Focal Spot, Summer 1986 [PDF]

, 1986
https://digitalcommons.wustl.edu/focal_spot_archives/1043/thumbnail ...

core   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

PAIN MANAGEMENT IN LUNG CANCERS : EXPERIENCE OF THE MEDICAL ONCOLOGY DEPARTMENT OF HASSAN II HOSPIATL IN FEZ

, 2023
I. Stitou, Oumaima Siyouri, Karima Alaoui Ismaili, M. Ismaili, L. Amaadour, K. Oualla, S. Arifi, Z. Benbrahim, N. Mellas, Sidi Mohamed Ben Abdellah University of Fez, Faculty of Medicine., K. Oualla, Sidi Mohamed Ben Abdellah University of Fez, Faculty of Medicine., S. Arifi, Sidi Mohamed Ben Abdellah University of Fez, Faculty of Medicine., Z. Benbrahim, Medical Oncology Department, Hassan II University Hospital, Fez, Morocco., N. Mellas, Medical Oncology Department, Hassan II University Hospital, Fez, Morocco.   +17 more
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Mental Wellbeing among Children with Cancer during COVID-19 Pandemic in Indonesia: A Cross-sectional Study

Indian Journal of Medical and Paediatric Oncology
Introduction Coronavirus disease 2019 (COVID-19) has affected both physical and mental aspect of people worldwide, especially the high-risk group such as pediatric cancer patients.
Teny Tjitra Sari, Tjhin Wiguna, Sylvia Detri Elvira, Indah Suci Widyahening, Rinoldy Mangiri, Apul S. Napitupulu, Nathania Sutandi, Silvia Tanumiharjo, R S. Sitorus   +8 more
doaj   +1 more source

A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer. [PDF]

, 2019
The objective of this research was to develop a robust gene expression-based prognostic signature and scoring system for predicting overall survival (OS) of patients with high-grade serous ovarian cancer (HGSOC).
Hang, Bo, Jin, Yu-Lan, Mao, Jian-Hua, Snijders, Antoine M, Wang, Pin, Xiong, Guang-Wu, Yang, Shao-Min, Zhang, Xiao-Wei, Zhao, Yue   +8 more
core  

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source